Clinical trial · Interventional
Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight
NCT01349361CI-TRIAL-00004779unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Photodynamic Therapy (PDT) is an effective treatment of basal cell carcinomas (BCC) however the inconvenience of clinic attendance and discomfort during therapy are significant drawbacks. The objective of this study is to evaluate the effect of daylight-mediated PDT of BCC.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Basal Cell Carcinomas | Basal Cell Carcinoma | ONTOLOGY_EXACT | 0.90 |
| Photodynamic Therapy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Daylight mediated photodynamic therapy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Daylight-PDT
- interventionNames
- Procedure: Daylight mediated photodynamic therapy
Primary outcomes (1)
- measure
- complete disappearance of the BCC
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * superficial BCC Exclusion Criteria: * Immunosuppression
References
Publications (0)
Data not yet available
No reference posted for this study.